

Appl. No. 10/035,662
Amdt. Dated April 4, 2005
Reply to Office action of November 2, 2004

Amendments to the Specification:

Please replace the paragraph appearing at page 1, lines 7-10 with the following amended paragraph:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Patent Application Serial No. 09/378,019, filed August 19, 1999, now U.S. Patent No. 6,388,054, which is hereby incorporated by reference in its entirety, and which claims priority to U.S. Provisional Application Serial No. 60/097,210, filed August 20, 1998, and U.S. Provisional Application Serial No. 60/141,169, filed June 25, 1999.

Please replace the paragraph appearing at page 16, line 23 through page 17, line 10 with the following amended paragraph:

Cell growth and survival were measured by a rapid colorimetric assay based on the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Mosmann, J Immunol. Methods 65: 55-63, 1983, with minor modifications). Briefly, 1,000 normal lung fibroblasts or normal epithelial BEAS-2B cells, 1,000 or 5,000 viable non-SCLC cells or 10,000 viable SCLC cells were plated in 100 μ L of growth medium in 96-well flat-bottomed microtiter plates. Cells were incubated overnight to allow recovery. Compounds to be tested were added to the cells in triplicate in a range of concentrations and the cells were incubated at 37[[∞]] $^{\circ}$ C, 5% CO₂, with 100% humidity. Control cells were treated in the same way without antagonists. All wells had a final volume of 200 μ L. Plates were incubated for 4 days, allowing sufficient time for cell replication and compound-induced cell death to occur. On day 5, 25 μ L of a 2 mg/mL solution of MTT (Sigma) dissolved in RMPI-1640 was added to each well. The plate was incubated for 4 h at 37[[∞]] $^{\circ}$ C. The supernate was removed and the blue formazan complex was dissolved by adding 100 μ L of 0.02 N HCl in 75% isopropanol to all wells. Absorbance was immediately determined using a scanning multiwell plate reader. B9870

Appl. No. 10/035,662

Amdt. Dated April 4, 2005

Reply to Office action of November 2, 2004

caused 50% cell death at a concentration of 0.15 μ M under these conditions.

Please replace the paragraph appearing at page 19, lines 5-7 with the following amended paragraph:

Results of representative in vivo tests are given in FIGS. 1-[[8]] 7. For comparison, bradykinin antagonist peptide dimers B9870 and B10054 caused marked inhibition of growth of the SCLC line SHP-77 at a dose of 5 mg/kg/day.